Total Cost
Free shipping on all orders
To place an order please call (833) 812 - 0565

brand lastacaft 0.25% eye drops

In stock Manufacturer ALLERGAN INC. 00023429003
$227.19 / 3 Milliliters Drop Btl

Select Quantity

Prescription is required


Allergic Conjunctivitis

Alcaftadine is used for the prevention of ocular itching associated with allergic conjunctivitis. Efficacy of alcaftadine for this use has been demonstrated in several controlled conjunctival antigen challenge studies in patients 10 years of age and older with allergic conjunctivitis. Results of these studies indicate that in patients with allergic conjunctivitis who were challenged with conjunctival antigen at 15 minutes and 16 hours after receiving alcaftadine 0.25% ophthalmic solution or vehicle, alcaftadine was more effective than vehicle in preventing ocular itching. The onset of action for alcaftadine was rapid, with an effect on ocular itching observed at 3 minutes after conjunctival antigen challenge.

Avoidance of allergen and other triggering factors (e.g., irritants) and application of cold compresses and lubricating eye drops are the initial means of managing allergic conjunctivitis. Drug therapy generally is reserved for use when such avoidance is not possible or is ineffective and can include both prophylactic (e.g., mast-cell stabilizers) and symptomatic (e.g., topical and/or systemic antihistamines, topical vasoconstrictors, topical steroid and nonsteroidal anti-inflammatory agents [NSAIAs]) therapy. The specific therapy(ies) employed will depend on the characteristics and severity of the allergic conjunctivitis. For patients with seasonal allergic conjunctivitis, prophylaxis with a mast-cell stabilizer often is initiated before and maintained throughout the pollen season, and symptomatic therapy with other agents (e.g., topical antihistamines, topical NSAIAs) generally is initiated as necessary to provide acute relief. Topical corticosteroids usually are reserved for short-term use in patients with moderate to severe symptoms of allergic conjunctivitis.

Dosage and Administration


Alcaftadine is applied topically to the eye as an ophthalmic solution. The ophthalmic solution is for topical ophthalmic use only. Care should be taken to avoid contamination of the solution container.

Alcaftadine ophthalmic solution contains benzalkonium chloride, which may be absorbed by some soft contact lenses. Patients should be advised to remove their contact lenses prior to administration of each dose of alcaftadine ophthalmic solution. Patients whose eyes are not red may reinsert soft contact lenses after 10 minutes following administration of the ophthalmic solution.


Allergic Conjunctivitis

The recommended dosage of alcaftadine for the prevention of itching associated with allergic conjunctivitis in adults and children 2 years of age or older is 1 drop of a 0.25% solution in each eye once daily.

Special Populations

The manufacturer makes no special population recommendations at this time.



The manufacturer states that there are no known contraindications to the use of alcaftadine.


General Precautions


Alcaftadine ophthalmic solution is for topical ophthalmic use only. The ophthalmic solution should not be instilled while the patient is wearing contact lenses. Patients should be advised not to wear contact lenses if their eyes are red. The ophthalmic solution should not be used to treat contact lens-related irritation.(See Dosage and Administration: Administration.)

Specific Populations


Category B.


It is not known whether alcaftadine is distributed into milk following topical application to the eye. Because many drugs are distributed into milk, caution should be exercised when alcaftadine is used in nursing women.

Pediatric Use

Safety and efficacy of alcaftadine ophthalmic solution have not been established in children younger than 2 years of age. Pediatric patients 10 years of age or older were included in controlled clinical trials evaluating efficacy and safety of alcaftadine ophthalmic solution, and pediatric patients 3 years of age or older were included in environmental studies establishing safety of the drug. Efficacy of the drug in children 2-9 years of age was extrapolated from demonstrated efficacy in older children and adults.

Geriatric Use

No overall differences in safety or efficacy were observed between geriatric patients and younger patients.

Common Adverse Effects

The most common adverse ocular effects (reported in less than 4% of eyes treated with alcaftadine ophthalmic solution) include irritation, burning, and/or stinging upon instillation; redness; and pruritus. Common nonocular adverse effects (reported in less than 3% of patients receiving the drug) include nasopharyngitis, headache, and influenza.

Drug Interactions

No formal drug interaction studies have been performed to date.

Write Your Own Review

Your meds on autopilot. Forever.